PMID- 22971090
OWN - NLM
STAT- MEDLINE
DCOM- 20130920
LR  - 20220409
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 75
IP  - 4
DP  - 2013 Apr
TI  - Psychotropic drugs and risk of motor vehicle accidents: a population-based 
      case-control study.
PG  - 1125-33
LID - 10.1111/j.1365-2125.2012.04410.x [doi]
AB  - AIM: To examine comprehensively the relationship between exposure to four classes 
      of psychotropic drugs including antipsychotics, antidepressants, benzodiazepines 
      (BZDs) and Z-drugs, and motor vehicle accidents (MVAs). METHOD: The authors 
      conducted a matched case-control study of 5183 subjects with MVAs and 31 093 
      matched controls, identified from the claims records of outpatient service visits 
      during the period from 2000 to 2009. Inclusion criteria were defined as subjects 
      aged equal to or more than 18 years and involved in MVAs. Conditional logistic 
      regressions with covariates adjustment (including urbanity, psychiatric and 
      non-psychiatric outpatient visits and Charlson comorbidity score) were applied to 
      examine the effect of four classes of psychotropic drugs on MVAs. RESULTS: 
      Significant increased risk of MVAs was found in subjects taking antidepressants 
      within 1 month (adjusted odds ratio (AOR) 1.73, 95% confidence interval (CI) 
      1.34, 2.22), 1 week (AOR 1.71, 95% CI 1.29, 2.26), and 1 day (AOR 1.70, 95% CI 
      1.26, 2.29) before MVAs occurred. Similar results were observed in subjects 
      taking benzodiazepines (BZDs) (AOR 1.56, 95% CI 1.38, 1.75 for 1 month; AOR 1.64, 
      95% CI 1.43, 1.88 for 1 week, and AOR 1.62, 95% CI 1.39, 1.88 for 1 day) and 
      Z-drugs (AOR 1.42, 95% CI 1.14, 1.76 for 1 month, AOR 1.37, 95% CI 1.06, 1.75 for 
      1 week, AOR 1.34, 95% CI 1.03, 1.75 for 1 day), but not antipsychotics. Moreover, 
      significant dose effects of antidepressants (equal to or more than 0.6-1.0 DDD), 
      BZDs (equal to or more than 0.1-0.5 DDD) and Z-drugs (more than 1 DDD) were 
      observed, respectively, on the risk of experiencing an MVA. CONCLUSION: Taken 
      together, subjects taking antidepressants, BZDs and Z-drugs, separately, should 
      be particularly cautioned for their increasing risk of MVAs.
CI  - (c) 2012 The Authors. British Journal of Clinical Pharmacology (c) 2012 The British 
      Pharmacological Society.
FAU - Chang, Chia-Ming
AU  - Chang CM
AD  - Department of Psychiatry, Chang Gung Memorial Hospital, Lin-Kou & Chang Gung 
      University, Taoyuan, Taiwan.
FAU - Wu, Erin Chia-Hsuan
AU  - Wu EC
FAU - Chen, Chuan-Yu
AU  - Chen CY
FAU - Wu, Kuan-Yi
AU  - Wu KY
FAU - Liang, Hsin-Yi
AU  - Liang HY
FAU - Chau, Yeuk-Lun
AU  - Chau YL
FAU - Wu, Chi-Shin
AU  - Wu CS
FAU - Lin, Keh-Ming
AU  - Lin KM
FAU - Tsai, Hui-Ju
AU  - Tsai HJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Hypnotics and Sedatives)
RN  - 12794-10-4 (Benzodiazepines)
SB  - IM
MH  - *Accidents, Traffic
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents/*adverse effects
MH  - Antipsychotic Agents/*adverse effects
MH  - Benzodiazepines/*adverse effects
MH  - Case-Control Studies
MH  - Databases, Factual
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Hypnotics and Sedatives/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Taiwan
PMC - PMC3612731
EDAT- 2012/09/14 06:00
MHDA- 2013/09/21 06:00
PMCR- 2014/04/01
CRDT- 2012/09/14 06:00
PHST- 2011/11/21 00:00 [received]
PHST- 2012/07/25 00:00 [accepted]
PHST- 2012/09/14 06:00 [entrez]
PHST- 2012/09/14 06:00 [pubmed]
PHST- 2013/09/21 06:00 [medline]
PHST- 2014/04/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2125.2012.04410.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2013 Apr;75(4):1125-33. doi: 
      10.1111/j.1365-2125.2012.04410.x.